The IRGQ Knockout SK-HEP-1 Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-HEP-1 human hepatic adenocarcinoma cell line. This heterogeneous pool harbors targeted disruptions in the IRGQ gene, which encodes an immunity-related GTPase, resulting in a loss-of-function model for studying autophagy and innate immune signaling. The polyclonal nature captures a spectrum of editing events, enabling robust functional analyses without clonal expansion bias.
The SK-HEP-1 host cell line is an established model of human hepatic adenocarcinoma, originally derived from the ascites of a patient with liver cancer. These adherent epithelial cells exhibit key features of hepatocellular carcinoma, such as anchorage-independent growth and expression of liver-specific markers, making them valuable for tumor cell biology studies. SK-HEP-1 cells are frequently used in liver tumorigenesis, metastasis, and drug response research, and their use as a knockout background allows direct interrogation of gene function in a relevant cancer context.
IRGQ functions as an immunity-related GTPase that integrates signals from interferon and Toll-like receptor pathways to modulate autophagy. It is transcriptionally activated by interferon-alpha and interferon-gamma and operates downstream of TLR signaling cascades. IRGQ interacts with the ATG5-ATG12 conjugation complex and cardiolipin, influencing the lipidation of LC3 and turnover of p62. These interactions place IRGQ at the nexus of autophagy regulation and innate immune defense. Disruption of IRGQ is predicted to impair autophagic flux and alter mTOR and ULK1 signaling, disturbing protein and organelle homeostasis.
In the SK-HEP-1 hepatic adenocarcinoma background, ablation of IRGQ provides a relevant platform for dissecting autophagy-innate immunity crosstalk in liver cancer. Hepatocellular carcinoma cells often exploit autophagy for survival under metabolic stress and immune evasion. Loss of IRGQ may compromise autophagic clearance, leading to damaged organelles and altered cytokine production, reshaping the tumor microenvironment. This model is valuable for exploring how IRGQ-mediated regulation of mTOR and interferon signaling impacts sensitivity to chemotherapeutic and targeted agents, shedding light on drug resistance mechanisms in liver cancer.
Researchers can employ these IRGQ knockout polyclonal cells to assess autophagic flux by monitoring LC3-II and p62 via western blotting, or using chloroquine-based flux assays. The cells are suited for RT-qPCR profiling of interferon-stimulated genes to evaluate innate immune activation, as well as colony formation and cell viability assays for tumorigenic potential and drug response. By integrating these approaches, scientists can delineate the role of IRGQ in hepatocellular carcinoma progression and immune regulation. For technical inquiries or experimental design assistance, contact Ascent Research.
